Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine

Ken Goda 1,2, Tsuneaki Kenzaka 1,2,*, Shinsuke Yahata 3, Masanobu Okayama 4 and Hogara Nishisaki 1

1 Hyogo Prefectural Tamba Medical Center, Department of Internal Medicine, 2002-7 Iso, Hikami-cho, Tamba 669-3495, Japan; kenkenpetneed@yahoo.co.jp (K.G.); honssk-d@sanynet.ne.jp (H.N.)
2 Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, 2-1-5 Arata-cho, Hiyogo-ku, Kobe 652-0032, Japan
3 Hyogo Prefectural Harima-Himeji General Medical Center, Department of General Internal Medicine, 3-264 Kamiya-cho, Himeji 670-8560, Japan; yahata-jci@umin.ac.jp
4 Division of Community Medicine and Medical Education, Kobe University Graduate School of Medicine, 2-1-5 Arata-cho, Hiyogo-ku, Kobe 652-0032, Japan; okayamam@med.kobe-u.ac.jp
* Correspondence: smile.kenzaka@jichi.ac.jp; Tel.: +81-78-382-6732

Abstract: This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions.

Keywords: COVID-19 vaccine; adverse reactions; first dose; second dose

1. Introduction

Vaccination against infectious diseases is a cost-effective method of disease prevention, and achieving herd immunity is important to protect those who cannot be vaccinated for various reasons [1]. While multiple doses of the vaccine against SARS-CoV-2 are available, adverse reactions to COVID-19 vaccines have become a matter of concern, and the public’s hesitancy toward the vaccine is a major issue [2].

Reports from Europe and the United States suggest that the SARS-CoV-2 vaccine is highly effective and has minor, but serious, side effects [3]. In Japan, the BNT162b2 messenger ribonucleic acid (mRNA) vaccine (Comirnaty, BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) is being administered to healthcare workers. The mRNA vaccine is administered by intramuscular injection; upon receiving this injection, immune-competent cells, such as muscle and dendritic cells, produce an mRNA protein, and a portion of the protein is presented to the lymphocytes to elicit an immune response [4]. Aversion to side effects is widely recognized as a major reason for vaccine hesitancy, and transparent and independent evidence of safety are needed, especially for new vaccines [5].

In Japan, many reports of serious adverse reactions to COVID-19 vaccines have been published [6], but few studies have analyzed the frequency of adverse reactions [7]. Although adverse reactions are more frequently reported among women than among men...
and among younger people than among older people after immunization against COVID-19 [3,8], to our knowledge, no previous studies have investigated the impact of first-dose adverse reactions on second-dose adverse reactions. Clarifying the impact of first-dose adverse reactions on second-dose adverse reactions would help clinicians and recipients deal with adverse reactions and hesitancy toward receiving multiple doses. Hence, this study aimed to investigate the frequency of adverse reactions to the COVID-19 vaccine in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions.

2. Materials and Methods

2.1. Study Design

This was a prospective cohort study. The study was approved by the Ethics Committee of the Hyogo Prefectural Tamba Medical Center (approval number: Tan-I number 1305). Participants provided written informed consent for the use of the questionnaires and for the publication of the study results.

2.2. Participants

In March and April 2021, in a mass vaccination program, a COVID-19 mRNA vaccine (Comirnaty, BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) was administered to the hospital staff at Tamba Medical Center. The vaccination was performed at their request and with their consent. Staff members who had received two doses of vaccine were included in the study.

2.3. Setting

Participants were given a self-administered questionnaire regarding adverse reactions to the vaccine, and a standardized questionnaire on general health status, which was used to obtain information on the individual’s basic attributes. The questionnaires were numbered and distributed in two batches. The vaccination questionnaire collected data about the situation on the day of vaccination and symptoms (adverse reactions) up to the 14th day post-vaccination. Only participants who had data on the first and second doses were included in the analyses.

2.4. Data Collected from the Questionnaire

Data on the following characteristics were collected: age, sex, pregnancy status (women only), underlying conditions, body temperature at the time of vaccination, physical condition at the time of vaccination, and food/drug allergy history. Data were collected on the following local adverse reactions at the injection site: redness, swelling, induration, pain, heat sensation, pruritus, and a feeling of heaviness. Data were collected on the following systemic adverse reactions: fever, chills, headache, fatigue, nasal discharge, cough, nausea, diarrhea, difficulty in moving the arms, and numbness.

2.5. Definition of Underlying Conditions

The presence of one or more of the following conditions was defined as an underlying condition: cancer, autoimmune diseases, diseases associated with steroid/immunosuppressant use, renal disease, diabetes, hepatic disease, and pulmonary disease.

2.6. Main Factors

The main factors were (1) no control groups with respect to age (<40 years, 40–59 years, and ≥60 years), sex, and underlying disease, and (2) no control group with respect to the first-dose adverse reaction.

2.7. Primary Outcomes

The primary outcomes were adverse reactions after the second doses of vaccine and included adverse reactions (“none” or “any one of local and systemic adverse reactions”);
local adverse reactions (“none” or “any one of local adverse reactions”); and systemic adverse reactions (“none” or “any one of systemic adverse reactions”).

2.8. Statistical Analysis

Logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for age, sex, underlying conditions, and the first-dose adverse reaction for each primary outcome measure. The analyses were performed using the following three models:

- Model 1—Unadjusted ORs.
- Model 2—Adjusted for sex, age, and underlying conditions.
- Model 3—Model 2 + adjusted for a first-dose adverse reaction.

Stata MP version 16 (StataCorp, College Station, TX, USA) was used for all the analyses.

3. Results

The sample selection process is shown in the flowchart (Figure 1). Overall, 904 and 894 staff received a first and second dose of the vaccine, respectively (88.50% vaccination coverage); and 800 and 679 completed the first-dose and second-dose questionnaires, respectively (response rate: 75.95%). A total of 671 participants whose data on both vaccine doses were available were included in the analysis.

![Figure 1](image-url)

**Figure 1.** The flowchart of the sample selection process.

The basic attributes and the incidence of local and systemic adverse reactions in the 671 participants are shown in Table 1 (missing values were excluded from the analysis). The mean age ± standard deviation was 42.8 ± 15.1 years, and 74.8% of the participants were female. The majority of participants had no underlying conditions.
Table 1. Participants’ background characteristics and symptoms in the 2 weeks after vaccination according to age.

|                                            | Overall | <40 Years |        | 40–59 Years |        | 60 Years or Older |        |
|--------------------------------------------|---------|-----------|--------|-------------|--------|-------------------|--------|
|                                            | First Vaccination | Second Vaccination | First Vaccination | Second Vaccination | First Vaccination | Second Vaccination | First Vaccination | Second Vaccination |
|                                            | n = 671 | n = 274 | n = 273 | n = 295 | n = 294 | n = 100 | n = 103 |
| Sex                                        |         |         |         |         |         |         |         |
| Male                                       | 169     | 25.2    | 71      | 25.9    | 59      | 20.0    | 39      | 39.0    |
| Female                                     | 502     | 74.8    | 203     | 74.1    | 236     | 80.0    | 234     | 79.6    |
| Age (years: mean, SD)                      | 42.8    | 15.1    | 27.0    | 6.2     | 49.9    | 5.8     | 49.8    | 5.7     |
| Pregnant (female only)                     | 0       | 0.0     | 2       | 1.0     | 0       | 0.0     | 1       | 0.5     |
| Cancer/malignant tumor                     | 3       | 0.4     | 0       | 0.0     | 1       | 0.3     | 2       | 2.0     |
| Autoimmune conditions/diseases associated with steroid/immunosuppressant use | 27      | 4.0     | 9       | 3.3     | 11      | 3.7     | 7       | 7.0     |
| Renal disease                              | 5       | 0.7     | 2       | 0.7     | 1       | 0.3     | 1       | 0.3     |
| Diabetes                                   | 12      | 1.8     | 1       | 0.4     | 7       | 2.4     | 4       | 4.0     |
| Hepatic disease                            | 2       | 0.3     | 0       | 0.0     | 1       | 0.3     | 1       | 1.0     |
| Pulmonary disease                          | 15      | 2.2     | 8       | 2.9     | 6       | 2.0     | 2       | 1.0     |
| Body temperature at the time of vaccination (°C: mean, SD) | 36.4     | 0.3     | 36.4    | 0.3     | 36.4    | 0.3     | 36.4    | 0.3     |
| Good physical condition at the time of vaccination | 653     | 98.9    | 270     | 98.9    | 284     | 99.0    | 97      | 99.0    |
| Food/drug allergies                        | 68      | 10.2    | 28      | 10.3    | 29      | 9.9     | 11      | 11.2    |
| Localized symptoms                         |         |         |         |         |         |         |         |         |
| Redness at the injection site              | 57      | 8.8     | 31      | 11.5    | 20      | 7.0     | 6       | 6.4     |
| Swelling at the injection site             | 95      | 14.8    | 48      | 18.0    | 32      | 11.4    | 56      | 19.6    |
| Induration at the injection site           | 87      | 13.6    | 37      | 13.8    | 37      | 13.2    | 36      | 12.6    |
| Pain at the injection site                 | 518     | 79.0    | 222     | 82.2    | 235     | 81.3    | 220     | 75.3    |
Table 1. Cont.

| Overall | <40 Years | 40–59 Years | 60 Years or Older |
|---------|-----------|-------------|------------------|
|         | First Vaccination | Second Vaccination | First Vaccination | Second Vaccination | First Vaccination | Second Vaccination |
| n = 671 | n = 274 | n = 273 | n = 295 | n = 294 | n = 100 | n = 103 |
| Heat sensation at the injection site | 87 13.6 | 48 18.1 | 32 11.5 | 7 7.4 | 12 12.0 |
| Itching at the injection site | 46 7.2 | 19 7.1 | 21 7.5 | 4 4.3 | 18 17.8 |
| Heat sensation at the injection site | 283 44.1 | 129 48.0 | 129 46.4 | 25 26.9 | 38 36.9 |
| Swelling of the axilla on the side of inoculation | 12 1.9 | 4 1.5 | 4 1.5 | 4 4.3 | 3 3.1 |
| Other localized symptoms | 26 4.5 | 7 2.9 | 15 5.9 | 4 4.8 | 5 5.6 |
| Any localized symptoms | 598 89.1 | 251 91.6 | 268 90.8 | 255 86.7 | 77 77.0 | 72 69.9 |
| Systemic symptoms | | | | |
| Fever | 23 3.6 | 15 5.6 | 7 2.5 | 1 1.1 | 20 20.0 |
| Chills | 11 1.7 | 4 1.5 | 7 2.5 | 0 0.0 | 17 16.7 |
| Headache | 63 9.8 | 23 8.6 | 34 12.1 | 4 4.3 | 23 22.5 |
| Fatigue | 84 13.0 | 40 14.9 | 34 12.1 | 10 10.6 | 34 33.3 |
| Nasal discharge | 16 2.5 | 2 0.7 | 9 3.2 | 5 5.3 | 7 7.0 |
| Cough | 13 2.0 | 1 0.4 | 10 3.6 | 2 2.2 | 2 2.0 |
| Nausea | 12 1.9 | 3 1.1 | 9 3.2 | 0 0.0 | 0 0.0 |
| Diarrhea | 8 1.2 | 1 0.4 | 5 1.8 | 2 2.2 | 1 1.0 |
| Myalgia | 220 33.8 | 95 35.4 | 97 33.9 | 28 29.8 | 37 36.6 |
| Arthralgia | 27 4.2 | 8 3.0 | 15 5.3 | 96 33.6 | 4 4.3 | 14 13.9 |
| Difficulty moving the arms | 312 48.1 | 135 50.2 | 141 49.8 | 34 36.2 | 27 27.0 |
| Numbness | 23 3.6 | 8 3.0 | 13 4.6 | 20 7.0 | 2 2.2 | 2 2.0 |
| Other systemic symptoms | 28 4.5 | 7 2.7 | 18 6.6 | 33 12.4 | 3 3.4 | 7 7.6 |
| Any systemic symptoms | 438 65.3 | 188 68.6 | 197 66.8 | 236 80.3 | 51 51.0 | 68 66.0 |
| Any localized or systemic symptoms | 628 93.6 | 257 93.8 | 282 95.6 | 87 87.0 | 86 83.5 |

SD, standard deviation.
A total of 598 (89.1%)/564 (84.1%) participants had local reactions, 438 (65.3%)/537 (80.0%) had systemic reactions, and 628 (93.6%)/621 (92.6%) had local or systemic adverse reactions after the first and second doses, respectively.

Autoimmune conditions and diseases associated with steroid/immunosuppressant use included rheumatoid arthritis, hypo/hyperthyroidism, atopic dermatitis, and kidney transplant. After the first dose of vaccine, 22 (81.5%), 12 (44.4%), and 22 (81.5%) of the participants with autoimmune conditions or diseases associated with steroid/immunosuppressant use had local reactions, systemic reactions, and local or systemic adverse reactions, respectively. After the second dose of vaccine, 25 (92.6%), 14 (51.9%), and 25 (92.6%) of participants with autoimmune conditions or diseases associated with steroid/immunosuppressant use had local reactions, systemic reactions, and local or systemic adverse reactions, respectively.

Local adverse reactions after the first dose included pain at the vaccination site in 518 (79.0%), heaviness at the vaccination site in 283 (44.1%), and swelling at the vaccination site in 95 (14.8%) participants. Local adverse reactions after the second dose included pain at the vaccination site in 490 (73.9%), heaviness at the vaccination site in 329 (50.0%), and swelling at the vaccination site in 155 (23.8%) participants.

The most common systemic adverse reactions after the first dose were difficulty in moving the arms in 312 (48.1%), myalgia in 220 (33.8%), and fatigue in 84 (13.0%) participants. The most common systemic adverse reactions after the second dose were fatigue in 398 (60.8%), headache in 295 (45.1%), myalgia in 279 (42.8%), and difficulty in moving the arms in 269 (41.8%) participants. Fever occurred in only 23 participants (3.6%) after the first dose, and in 264 participants (40.7%) after the second dose.

If there was an adverse reaction after the first dose, the risk of any adverse reaction after the second dose was significantly higher (adjusted OR (aOR): 49.6, 95% CI: 21.96–112.16). Males were significantly less likely to experience an adverse reaction than females (aOR: 0.36, 95% CI: 0.17–0.76) (Table 2).

Table 2. Factors associated with any adverse reaction (either local or systemic adverse reaction), after the second dose of COVID-19 mRNA vaccine.

|                          | Model 1 OR (95% CI) | Model 2 aOR (95% CI) | Model 3 aOR (95% CI) |
|--------------------------|---------------------|----------------------|---------------------|
| Sex                      |                     |                      |                     |
| Female                   | Reference           | Reference            | Reference           |
| Male                     | 0.23 (0.13–0.42)    | 0.25 (0.14–0.46)     | 0.36 (0.17–0.76)    |
| Age                      |                     |                      |                     |
| <40 years                | Reference           | Reference            | Reference           |
| 40–59 years              | 1.71 (0.83–3.51)    | 1.52 (0.73–3.16)     | 1.71 (0.71–4.14)    |
| 60 years or older        | 0.40 (0.20–0.80)    | 0.39 (0.18–0.83)     | 0.51 (0.20–1.32)    |
| Underlying conditions    |                     |                      |                     |
| No                       | Reference           | Reference            | Reference           |
| Yes                      | 1.06 (0.50–2.24)    | 1.71 (0.75–3.94)     | 1.08 (0.41–2.86)    |
| Adverse reaction to first dose |                     |                      |                     |
| No                       | Reference           | ...                  | Reference           |
| Yes                      | 59.87 (27.66–129.58) | ...                 | 49.63 (21.96–112.16) |

Model 1: unadjusted; Model 2: adjusted for sex, age, and underlying conditions; Model 3: Model 2 + adjusted for adverse reaction to first dose. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.

Among those aged 60 years and older, the aOR of developing local adverse reactions compared with those aged under 40 years was 0.35 (95% CI: 0.18–0.66) (Table 3). The reactions were significantly more likely to occur after the second dose of vaccine (aOR: 18.37 (95% CI: 8.68–38.86).
Table 3. Factors associated with local adverse reactions after the second dose of COVID-19 mRNA vaccine.

|                          | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) |
|--------------------------|---------------------|---------------------|---------------------|
| **Sex**                  |                     |                     |                     |
| Female                   | Reference           | Reference           | Reference           |
| Male                     | 0.50 (0.32–0.77)    | 0.53 (0.34–0.83)    | 0.82 (0.44–1.22)    |
| **Age**                  |                     |                     |                     |
| <40 years                | Reference           | Reference           | Reference           |
| 40–59 years              | 1.03 (0.63–1.66)    | 0.94 (0.58–1.54)    | 0.92 (0.54–1.22)    |
| 60 years or older        | 0.36 (0.21–0.63)    | 0.32 (0.18–0.57)    | 0.35 (0.18–0.66)    |
| **Underlying conditions**|                     |                     |                     |
| No                       | Reference           | Reference           | Reference           |
| Yes                      | 1.27 (0.73–2.22)    | 1.90 (1.03–3.50)    | 1.63 (0.85–3.10)    |
| **Adverse reaction to first dose** |                     |                     |                     |
| No                       | Reference           |                     |                     |
| Yes                      | 21.45 (10.38–44.34) |                     | 18.37 (8.68–38.86)  |

Model 1: unadjusted; Model 2: adjusted for sex, age, and underlying conditions; Model 3: Model 2 + adjusted for adverse reaction to first dose. Abbreviations: OR, odds ratio; CI, confidence interval.

Participants with a systemic adverse reaction after the first dose of the vaccine were more than 10 times more likely to have a systemic adverse reaction after the second dose (aOR: 10.62, 95% CI: 5.13–21.99) (Table 4). Systemic adverse reactions were also less common in males than in females (aOR: 0.41, 95% CI: 0.27–0.64), and the risk of a systemic adverse reaction decreased with increasing age (Table 4).

Table 4. Factors associated with systemic adverse reactions after the second dose of COVID-19 mRNA vaccine.

|                          | Model 1 OR (95% CI) | Model 2 aOR (95% CI) | Model 3 aOR (95% CI) |
|--------------------------|---------------------|----------------------|----------------------|
| **Sex**                  |                     |                      |                      |
| Female                   | Reference           | Reference            | Reference            |
| Male                     | 0.34 (0.23–0.51)    | 0.35 (0.23–0.53)     | 0.41 (0.27–0.64)     |
| **Age**                  |                     |                      |                      |
| <40 years                | Reference           | Reference            | Reference            |
| 40–59 years              | 0.72 (0.46–1.12)    | 0.64 (0.41–1.01)     | 0.61 (0.38–0.98)     |
| 60 years or older        | 0.34 (0.20–0.58)    | 0.33 (0.19–0.58)     | 0.37 (0.20–0.67)     |
| **Underlying conditions**|                     |                      |                      |
| No                       | Reference           | Reference            | Reference            |
| Yes                      | 1.01 (0.62–1.64)    | 1.48 (0.87–2.53)     | 1.29 (0.74–2.23)     |
| **Adverse reaction to first dose** |                     |                      |                      |
| No                       | Reference           |                      |                     |
| Yes                      | 13.17 (6.55–26.49)  |                      | 10.62 (5.13–21.99)   |

Model 1: unadjusted; Model 2: adjusted for sex, age, and underlying conditions; Model 3: Model 2 + adjusted for adverse reaction to first dose. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.

4. Discussion

In this study, local or systemic adverse reactions following COVID-19 vaccination were reported by more than 90% of the participants. Participants with adverse reactions after the first dose were significantly more likely to experience adverse reactions after the second dose. Although it has been reported that adverse reactions are more common after the first dose than after the second one [3,8], to our knowledge, this is the first report to show that...
adverse reactions to the first dose of vaccine were associated with a substantially increased risk of adverse reactions to the second dose. In addition, the incidence of systemic adverse reactions was higher after the second dose than after the first dose. As in previous studies, local and systemic adverse reactions were significantly more likely to occur in women than in men, and in younger adults than in older adults [3,8].

In terms of the association between the first-dose and second-dose adverse reactions, the proportion of local reactions did not increase after the second dose, and none of the participants reported Grade 4 local reactions [3]. In general, most local reactions were mild-to-moderate and resolved within 1–2 days. However, the reported incidence of systemic adverse reactions was higher after the second dose than after the first dose, as in previous studies [3,8]. Izumo et al. [8] reported a higher incidence of adverse reactions, including a higher incidence of Grade 3 adverse reactions after the second dose than after the first dose; this study also examined the evolution of antibody titers after COVID-19 vaccination and found that only 35% of the participants had positive antibody titers after the first vaccination, and all of them showed positive titers after the second vaccination. These results suggest that two doses are necessary to obtain COVID-19 prophylaxis in the clinical setting [9]. Furthermore, after the second dose, the antibody titers were significantly negatively correlated with age. This means that older people have lower antibody titers than younger people, which may be associated with the lower incidence of adverse effects from vaccination in the older age groups. Therefore, there may be a correlation between antibody titers and adverse reactions [8].

In a study of healthy adults in Australia and the Philippines, the incidence of both local and systemic adverse reactions to the influenza vaccination was reported to be around 50% [10], but in a Japanese study of medical professionals, the incidence of local reactions was 73.9–81% [11]. However, in another Japanese study of medical professionals, the occurrence of local reactions was reported to be 73.9–81.7%, and that of systemic adverse reactions, 15.8–20.0% [11,12]. The COVID-19 vaccine showed a slightly higher frequency of local adverse reactions (89.1% for the first dose and 84.1% for the second dose). In a multinational clinical trial of the BNT162b2 vaccine, the incidence of serious adverse events was reported to be low and comparable between the vaccine and placebo groups [3]. However, when minor adverse reactions were included in the analysis, the overall incidence rates were 93.6% after the first dose and 92.5% after the second dose, and the incidence rates of systemic adverse reactions were slightly higher than those of local reactions at 65.3% and 80.0%, respectively.

In our study, participants with autoimmune diseases or diseases associated with steroid/immunosuppressant use had a lower risk of systemic adverse reactions than other participants. Although there were no participants in this study that had myasthenia gravis, vaccines against SARS-CoV-2 showed good short-term safety in myasthenia gravis patients, who may take advantage of the vaccination with regard to avoiding life-threatening complications, such as COVID-19 pneumonia [13]. After the first dose, 70.8% experienced adverse events, which consisted of local pain (76.5%), asthenia (29.4%), cephalalgia (17.6%), myalgia (5.9%), and with four patients (23.5%) experiencing two or more adverse reactions. No patients experienced fever after the first dose. There may be a correlation between antibody titers and adverse reactions [13].

The most common local adverse reactions caused by the influenza vaccine are injection site pain (75.6%), injection site swelling (18%), and injection site redness (10.4%) [11], similar to the common local adverse reactions caused by the COVID-19 vaccine. In contrast, the common systemic adverse reactions caused by the influenza vaccine include fatigue (8.7%), difficulty moving the arm (7.1%), and headaches (4.9%) [12], while the COVID-19 vaccine causes many other systemic adverse reactions; for example, in a study published in Germany, the most common systemic adverse reactions were headache/fatigue (48.1%), followed by myalgia (28.1%), fatigue (18.8%), arthralgia (14.3%), chills (13.9%), and fever (9.9%) [14]. The safety report of the Centers for Disease Control and Prevention on the BNT162b2 vaccine among volunteers in phase III trials included headache/fatigue (44.1%),
myalgia (25.4%), chills (19.7%), arthralgia (15%), and fever (7.9%) as the most common systemic adverse reactions [15], which is similar to the findings of the current study.

In an international phase 2/3 study by Polack et al. [3], systemic adverse reactions were more common in younger (16–55 years) than in older (55 years and older) participants, and more common after the second dose of the vaccine than after the first dose. Fever (body temperature of 38 °C or higher) was reported to occur in 16% of the young and 11% of the older participants after the second vaccination and in 4% and 1%, respectively, after the first vaccination [3]; the median age in this study was 52 years, and 42% of the participants were aged 55 years or older. On the other hand, a Japanese study of healthcare workers reported an increase in the incidence of fever from 3.0% after the first dose to 44.9% after the second dose [8]. Our results (3.6% to 40.7%, respectively) were similar to a previous study [8]. This finding can be attributed to the fact that the definition of fever was 37.5 °C or higher, and the participants were relatively young. Other systemic symptoms, such as chills, headache, fatigue, and arthralgia, were also more common after the second dose.

In our study, local and systemic adverse reactions were less common among those aged 60 years or older, and systemic adverse reactions were more common among those younger than 40 years and 40–59 years. Other studies have also found that adverse reactions are more common in younger individuals than in older individuals [14,16]. Adverse reactions to vaccines are thought to be a byproduct of excessive production of type I interferon (IFN-I), which initiates an effective immune response against invading pathogens [17]. The production of IFN-I in women and young adults has been found to be greater than that in men and older adults [17,18], so this may explain the higher incidence of adverse reactions in women and younger adults than in men and older adults.

In the present study, some local and systemic adverse reactions occurred at a significantly lower rate in men. This is consistent with previous reports of more frequent adverse reactions in women [8,19–21]. The incidence of adverse reactions has been reported to be higher in women than in men after receiving mRNA-based and inactivated viral vaccines [19]. Women have consistently been shown to have an increased risk of adverse reactions after immunization with viral vaccines, such as influenza, measles-mumps-rubella combined vaccine, attenuated Japanese encephalitis vaccine, and attenuated dengue vaccine, and women tend to show vigorous immune responses [20].

Polyethylene glycol (PEG) has also been implicated as a cause of anaphylaxis in women [21]. Polyethylene glycol (PEG) is found in mRNA vaccines. PEG is also used in shampoos, toothpaste, and cosmetics. Women use cosmetics more frequently than men and have more exposure on a regular basis. Patients previously exposed to PEG may have high levels of antibodies to PEG and may be at risk for anaphylactic reactions to vaccines [21]. Although no anaphylaxis occurred in this study, these mechanisms may explain the increased incidence of adverse reactions in women and younger people.

Participants with autoimmune conditions and conditions associated with steroid/immunosuppressant use were less likely to develop systemic reactions compared with other participants. The second dose might represent a more vigorous response from crossing T cells or antibodies against antigens or anaphylaxis after a sensitization process. Therefore, healthcare providers should carefully collect information on reactions to the first dose so as to be prepared for adverse reactions after the second dose. This information may also help individuals to make informed decisions about vaccinations and help with the use of antihistamines, steroids, and other anti-allergy medications prior to vaccination.

Limitations

We did not conduct regular observations to monitor the occurrence of adverse reactions, but collected data based on self-reports instead. As the participants were healthcare professionals, the reliability of the self-reports is likely to have been high, but the possibility of inconsistencies in reporting due to subjectivity cannot be ruled out. As the participants were medical professionals, there is also a possibility of selection bias. This may limit the
generalizability of these results. The degree of adverse reactions was not quantified, and difference in the degree of adverse reactions after each dose was not assessed.

5. Conclusions

Vaccination with an mRNA-based COVID-19 vaccine caused local or systemic adverse reactions in approximately 90% of the study participants. Participants with an adverse reaction after the first dose were more than ten-fold more likely to experience an adverse reaction after the second dose. Adverse reactions were more common in women than in men. Local adverse reactions were less common among younger participants than older participants, and the risk of adverse reaction decreased significantly with increasing age.

Healthcare providers should carefully collect information on reactions to the first dose, and should be prepared for adverse reactions after the second dose. These study results could also help individuals to make informed decisions about COVID-19 vaccination.

Author Contributions: Conceptualization, K.G. and T.K.; methodology, T.K.; formal analysis, S.Y.; investigation, K.G.; data curation, S.Y.; writing—original draft preparation, K.G.; writing—review and editing, T.K.; supervision, M.O.; project administration, H.N. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Hyogo Prefectural Tamba Medical Center (approval number: Tan-I number 1305).

Informed Consent Statement: Informed consent was obtained from all study participants. Written informed consent has been obtained from the participants to publish this paper.

Data Availability Statement: The data sets used and/or analyzed during the present study are available from the first author on reasonable request.

Acknowledgments: The authors would like to thank the Infection Control Office of Hyogo Prefectural Tamba Medical for administering the vaccine and providing information on adverse reactions to influenza vaccines.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Leidner, A.J.; Murthy, N.; Chesson, H.W.; Biggerstaff, M.; Stoeker, C.; Harris, A.M.; Acosta, A.; Doeling, K.; Bridges, C.B. Cost-effectiveness of adult vaccination: A systematic review. Vaccine 2019, 37, 226–234. [CrossRef]
2. Bauernfeind, S.; Hitzenbichler, F.; Huppertz, G.; Zeman, F.; Koller, M.; Schmidt, B.; Plentz, A.; Bauswein, M.; Mohr, A.; Salzberger, B. Brief report: Attitudes towards COVID-19 vaccination among hospital employees in a tertiary care university hospital in Germany in December 2020. Infection 2021, 49, 1307–1311. [CrossRef]
3. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [CrossRef]
4. Teo, S.P. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. Pharm. Pract. 2021, 8971900211009650, Epub ahead of print. [CrossRef]
5. MacDonald, M.E. Vaccine hesitancy: Definition, scope, and determinants. Vaccine 2015, 33, 4161–4164. [CrossRef]
6. Kawata, K.; Nakabayashi, M. Determinants of COVID-19 vaccine preference: A survey study in Japan. SSM Popul. Health 2021, 15, 100902. [CrossRef]
7. Otani, J.; Ohta, R.; Sano, C. Association between immunoglobulin G levels and adverse effects following vaccination with the BNT162b2 vaccine among Japanese healthcare workers. Vaccines 2021, 9, 1149. [CrossRef]
8. Izumo, T.; Kuse, N.; Awano, N.; Tone, M.; Sakamoto, K.; Takada, K.; Muto, Y.; Fujimoto, K.; Saiki, A.; Ito, Y.; et al. Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan. Respir. Investig. 2021, 59, 635–642. [CrossRef]
9. Luo, C.; Liu, M.; Li, Q.; Zheng, X.; Ai, W.; Gong, F.; Fan, J.; Liu, S.; Wang, X.; Luo, J. Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Multiple factor-based analysis. Int. J. Infect. Dis. 2021, 108, 57–62.
10. Cadorna-Carlos, J.B.; Nolan, T.; Borja-Tabora, C.F.; Santos, J.; Montalban, M.C.; de Loosje, F.J.; Eizenberg, P.; Hall, S.; Dupuy, M.; Hutagalung, Y.; et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized controlled phase III trial. Vaccine 2015, 33, 2485–2492. [CrossRef]
11. Watanabe, K.; Matsumoto, S.; Toyoshima, E. Adverse drug reaction following quadrivalent influenza vaccination coverage of health care workers. *Jpn. J. Environ. Infect.* 2016, 31, 397–401.
12. Kenzaka, T.; Yahata, S.; Goda, K.; Kumabe, A.; Kamada, M.; Okayama, M. Effects of vaccination day routine activities on influenza vaccine efficacy and vaccination-induced adverse reaction incidence: A cohort study. *Vaccines* 2021, 9, 753. [CrossRef]
13. Lupica, A.; Di Stefano, V.; Iacono, S.; Pignolo, A.; Quartana, M.; Gagliardo, A.; Fierro, B.; Brighina, F. Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: Data from an Italian cohort. *Neural. Int.* 2022, 14, 406–416. [CrossRef]
14. Klugar, M.; Riad, A.; Mekhemar, M.; Conrad, J.; Buchbender, M.; Howaldt, H.P.; Attia, S. Side effects of mRNA-Based and viral vector-based COVID-19 vaccines among German healthcare workers. *Biology* 2021, 10, 752. [CrossRef]
15. Centres for Disease Control and Prevention. Reactions and Adverse Events of Pfizer-BioNTech COVID-19 Vaccine. Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html (accessed on 7 March 2021).
16. Riad, A.; Pokorná, A.; Attia, S.; Klugarová, L.; Koščík, M.; Klugar, M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. *J. Clin. Med.* 2021, 10, 1428. [CrossRef]
17. Sprent, J.; King, C. COVID-19 vaccine side effects: Positive feelings about feeling bad. *Sci. Immunol.* 2021, 6, eabj9256. [CrossRef]
18. Bunders, M.J.; Altfield, M. Implications of sex differences in immunity against SARS-CoV-2 pathogenesis and the design of therapeutic interventions. *Immunity* 2020, 53, 487–495. [CrossRef]
19. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.; Almukadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi, N.; et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. *Int. J. Gen. Med.* 2021, 14, 1389–1401. [CrossRef]
20. Klein, S.L.; Jedlicka, A.; Pekosz, A. The Xs and Y of immune responses to viral vaccines. *Lancet Infect. Dis.* 2010, 10, 338–349. [CrossRef]
21. Klimek, L.; Eckrich, J.; Hagemann, J.; Casper, I.; Hupfertz, J. Allergic reactions to COVID-19 vaccines: Evidence and practice-oriented approach. *Internist* 2021, 62, 326–332. [CrossRef]